|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.610 USD | +0.23% |
|
-.--% | - |
| 18/25/18 | Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Microcap Index | CI |
| 18/25/18 | Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 3000E Index | CI |
| Market Cap | 39Cr 34Cr 31Cr 29Cr 55Cr 3.72TCr 55Cr 367.66Cr 143.35Cr 1.81TCr 146.83Cr 143.7Cr 6.27TCr | P/E Ratio 2023 |
-13.9x | P/E Ratio 2024 | -11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 32Cr 28Cr 26Cr 24Cr 45Cr 3.09TCr 46Cr 305.25Cr 119.01Cr 1.5TCr 121.9Cr 119.31Cr 5.2TCr | EV / Sales 2023 |
25,97,077x | EV / Sales 2024 | 32,42,111x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: YMAS THER
| 1 day | +0.23% |
| 1 year | 3.9 |  | 8.61 |
| 3 years | 3.55 | | 20.9 |
| 5 years | 2.7 | | 39.82 |
| 10 years | 2.7 | | 55.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Vanessa Wolfeler
PSD | President | - | 16/09/2025 |
| Chief Tech/Sci/R&D Officer | 75 | 01/01/2016 | |
Daniel Dolan
TRE | Treasurer | - | 16/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Vanessa Wolfeler
BRD | Director/Board Member | - | 16/09/2025 |
Robert Duffield
BRD | Director/Board Member | - | 16/09/2025 |
Daniel Dolan
BRD | Director/Board Member | - | 16/09/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/25/16 | Sofinnova Investments, Inc.
| Tender | Company | 21,94,278 | 4.8991% | |
| 16/25/16 | Issuer sale | Chief Financial Officer | 3,43,100 | 0.7660% | ||
| 16/25/16 | Issuer sale | Director | 1,70,850 | 0.3815% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 84.82 73.26 67.51 63.19 118.42 8.06T 120.26 797.11 310.79 3.92T 318.33 311.55 13.59T | 87.68 75.73 69.79 65.33 122.42 8.33T 124.32 824.05 321.29 4.06T 329.08 322.08 14.05T |
| Net income | -2.14Cr -1.85Cr -1.71Cr -1.6Cr -2.99Cr -203.66Cr -3.04Cr -20Cr -7.85Cr -99Cr -8.04Cr -7.87Cr -343.24Cr | -2.97Cr -2.56Cr -2.36Cr -2.21Cr -4.14Cr -281.98Cr -4.21Cr -28Cr -11Cr -137.25Cr -11Cr -11Cr -475.22Cr |
| Net Debt | -7.72Cr -6.67Cr -6.15Cr -5.75Cr -11Cr -733.96Cr -11Cr -73Cr -28Cr -357.25Cr -29Cr -28Cr -1.24TCr | -6.64Cr -5.74Cr -5.29Cr -4.95Cr -9.27Cr -631.27Cr -9.42Cr -62Cr -24Cr -307.26Cr -25Cr -24Cr -1.06TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- YMAB Stock
Select your edition
All financial news and data tailored to specific country editions
